{"id":250,"date":"2024-05-20T18:03:47","date_gmt":"2024-05-20T10:03:47","guid":{"rendered":"https:\/\/cytoarm.com\/?p=250"},"modified":"2024-09-09T08:55:30","modified_gmt":"2024-09-09T00:55:30","slug":"innovative-armed-t-technology-for-cancer-treatment","status":"publish","type":"post","link":"https:\/\/cytoarm.com\/zh\/post\/250\/","title":{"rendered":"\u8cfd\u6602\u751f\u91ab CEO \u7372\u5f97\u53f0\u7063\u74b0\u7403\u751f\u6280\u6700\u4f73CEO\u734e"},"content":{"rendered":"

Date:<\/strong> January 10, 2024
Dr. Kuo-Hsiang Chuang Recognized for Pioneering Cancer Therapy<\/strong>
For more details, visit Global Bio & Investment<\/a>.<\/p>\n\n\n\n

CytoArm’s CEO, Dr. Kuo-Hsiang Chuang, has been named Taiwan’s top young biomedical leader by Global Bio & Investment Magazine. This accolade highlights his groundbreaking work in developing the Armed-T cell technology, a non-viral gene modification method that offers a safer and more effective cancer treatment alternative. Dr. Chuang’s dedication and innovation are paving the way for new advancements in cancer therapy, bringing hope to patients worldwide.<\/p>\n\n\n\n

Technology Overview<\/h3>\n\n\n\n
    \n
  • Professor Kuang-Hsiang Chuang and his team at CytoArms Biotechnology developed the Armed-T technology.<\/li>\n\n\n\n
  • Unlike traditional CAR-T therapy, Armed-T does not require viral gene modification.<\/li>\n\n\n\n
  • T-cells are directly equipped with personalized anti-cancer armor.<\/li>\n\n\n\n
  • These Armed-T cells effectively recognize and attack tumors.<\/li>\n<\/ul>\n\n\n\n

    Clinical Trials and Potential Impact<\/h3>\n\n\n\n
      \n
    • The product CTA-02, based on Armed-T technology, is entering phase I clinical trials.<\/li>\n\n\n\n
    • It has the potential to challenge the current leading CAR-T immunotherapy.<\/li>\n\n\n\n
    • Professor Chuang emphasizes the life-saving potential of this technology for cancer patients.<\/li>\n<\/ul>\n\n\n\n
      \"News2<\/figure>","protected":false},"excerpt":{"rendered":"

      Date: January 10, 2024Dr. Kuo-Hsiang Chuang Recognized for Pioneering Cancer TherapyFor more details, visit Global Bio & Investment. CytoArm’s CEO, Dr. Kuo-Hsiang Chuang, has been named Taiwan’s top young biomedical leader by Global Bio & Investment Magazine. This accolade highlights his groundbreaking work in developing the Armed-T cell technology, a non-viral gene modification method that […]<\/p>\n","protected":false},"author":3,"featured_media":252,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_gspb_post_css":"","footnotes":""},"categories":[20],"tags":[],"class_list":["post-250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-updates"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/posts\/250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/comments?post=250"}],"version-history":[{"count":0,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/posts\/250\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/media\/252"}],"wp:attachment":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/media?parent=250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/categories?post=250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/tags?post=250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}